| Study/year | Geographic location | Tumour site(s) | No. of cases | HPV +ve (%) | Genotype(s) | DNA method |
|
Loning et al., 1985 [48] | Germany | Oscc | 6 | 50% | 16, 11 | SB | Maitland et al., 1987 [49] | United Kingdom | Oscc | 15 | 46.7% | 16 | SB | Gassenmaier and Hornstein, 1988 [50] | Germany | Oscc | 68 | 23.5% | 16 | ISH |
Syrjänen et al., 1988 [51] | Finland | Oscc | 51 | 11.8% | 16, 18 | ISH | Chang et al., 1990 [52] | Finland | Oscc | 40 | 2.5; 27.5% | 16 | ISH; PCR | Greer et al., 1990 [53] | USA | Oscc | 100 | 6% | n.d | ISH | Kashima et al., 1990 [54] | USA | Oscc | 26 | 19.2% | | SB | Young and Min et al., 1991 [55] | USA | Oscc | 27 |
0% | 6, 11, 16, 18, 31, 33, 35 | PCR | Zeuss et al., 1991 [56] | Spain | Oscc | 15 | 0% | 6, 11 | ISH |
Holladay and Gerald, 1993 [57] | USA | Oscc | 39 | 17.9% | 16 | PCR | Cox et al., 1993 [58] | UK | Oscc | 8 | 50% | 16 | SB | Brandwein et al., 1994 [59] | USA | Oscc | 64 | 25% | 16 | PCR |
González-Moles et al., 1994 [60] | Spain | Oscc | 27 | 37% | 6, 11 | ISH | Ostwald et al., 1994 [61] | Germany | Oscc | 26 | 61.5% | 16, 18 | PCR | Balaram et al., 1995 [62] | India | Oscc | 91 | 73.6% | 6, 11, 16, 18 | PCR | Shindoh et al., 1995 [63] | Japan | Oscc | 77 | 31.2% | 16 | PCR | Van Rensburg et al., 1995 [64] | South Africa | Oscc | 66 | 1.5% | 18 | ISH | Cruz et al., 1996 [65] | The Netherlands | Oscc | 35 | 54.3% | 16 | PCR | Mao et al., 1996 [66] | USA | Oscc | 64 | 31% | n.d. | PCR | Van Rensburg et al., 1996 [67] | South Africa | Oscc | 146 | 1.4% | 11, 16 | PCR | Chiba et al., 1996 [68] | Japan | Oscc | 38 | 21% | 16, 18, 33 | PCR | Wen et al., 1997 [69] | Japan | Oscc | 45 | 31.1% | 16, 18 | PCR | Gopalakrishnan et al., 1997 [70] | USA | Oscc | 10 | 30% | 16 | PCR | Ibrahim et al., 1998 [71] | Sudan | Oscc | 88 |
0; 0% | n.d. | ISH; PCR | Koh et al., 1998 [72] | Korea | Oscc | 42 | 52% | n.d. | PCR | Premoli-De-Percoco et al., 1998 [73] | Venezuela | Oscc | 50 | 70% | 16, 18 | ISH |
D’Costa et al., 1998 [74] | India | Oscc | 100 | 15% | 16, 18 | PCR | Schwartz et al., 1998 [33] | USA | Oscc | 193 | 21.2% | 16 | PCR | Elamin et al., 1998 [75] | UK | Oscc | 28 | 50% | 6, 16 | PCR | Aggelopoulou et al., 1999 [76] | Greece | Oscc | 81 | 49% | n.d | PCR | Pillai et al., 1999 [77] | India | Oscc | 61 | 16.8% | 16 | PCR | Pintos et al., 1999 [78] | Canada | Oral cavity | 29 | 10% | n/s | PCR | Badaracco et al., 2000 [79] | Italy | Oscc | 66 | 36.4% | 16, 6 | PCR | Bouda et al., 2000 [80] | Greece | Oscc | 19 | 94.7% | 16, 18, 33 | PCR | Cao et al., 2000 [81] | China | Oscc | 40 | 72.5% | 16, 18 | PCR |
Patima Cao et al., 2000 [82] | China | Oscc | 73 | 74% | 16, 18 | PCR | Sand et al., 2000 [83] | Sweden | Oscc | 24 | 12.5% | 16, 18, 6, 11 | PCR | Tsuhako et al., 2000 [84] | Japan | Oscc | 83 | 56.9% | n.d. | PCR | Gillison et al., 2000 [30] | USA | Oscc | 84 | 11.9% | 16 | PCR & ISH & SB | Bouda et al., 2000 [80] | Greece | Oscc | 19 | 89.5% | 16, 18 | PCR |
Premoli-De-Percoco and Ramirez 2001 [85] | Venezuela | Oscc | 50 | 60% | 16, 18 | PCR | Schwartz et al., 2001 [86] | USA | Oscc | 254 | 24.4% | 16 | PCR | Chen et al., 2002 [87] | Taiwan | Oscc | 29 | 82.7% | 16, 18, 6 | PCR | Kojima et al., 2002 [88] | Japan | Oscc | 53 | 66% | 38 | PCR | Nagpal et al., 2002 [89] | India | Oscc | 110 | 33.6% | 16, 18 | PCR | Chang et al., 2003 [90] | Japan | Oscc | 103 | 49.5% | HR | PCR | Fregonesi et al., 2003 [91] | Brazil | Oscc | 46 | 39% | 16, 18, 6, 11 | ISH | Kansky et al., 2003 [92] | Slovenia | Oscc | 62 | 95% | 16, 33, 58, 11, 31, 68 | PCR | Ritchie et al., 2003 [93] | USA | Oscc | 141 | 15% | 16, 33 | PCR | Sugiyama et al., 2003 [94] | Japan | Oscc | 86 | 34.8% | 16 | PCR | Herrero et al., 2003 [95] | France | Oscc | 58 | 5.17% | 16 | PCR | Ostwald et al., 2003 [96] | Germany | Oscc | 118 | 43.2% | 6, 11, 16, 18 | PCR/SB | Correnti et al., 2004 [97] | Venezuela | Oscc | 16 | 50% | HR | PCR | Dahlgren et al., 2004 [98] | Sweden | Oscc | 110 | 10.9% | 16 | PCR | Smith et al., 2004 [99] | USA | Oscc | 106 | 9.4% | 16, 33 | PCR | Zhang et al., 2004 [100] | Japan | Oscc | 73 | 34% | 16, 18 | PCR | Yang et al., 2004 [101] | Taiwan | Oscc | 37 | 10.8% | 16, 18 | PCR | Koppikar et al., 2005 [102] | India | Oscc | 101 | 31.7% | 16, 18 | PCR | Lo Muzio et al., 2005 [103] | Italy | Oscc | 18 | 50% | n.d. | PCR | Boy et al., 2006 [104] | South Africa | Oscc | 59 | 11% | 18 | PCR; ISH |
El-Mofty and Patil 2006 [105] | USA | Oscc | 94 | 30% | 16, 31, 33 | PCR | Nemes et al., 2006 [106] | Hungary | Oscc | 79 | 41.7% | 16 | PCR |
Rivero and Nunes 2006 [107] | Brazil | Oscc | 23 | 0% | n.d. | PCR | Campisi et al., 2006 [108] | Italy | Oscc | 63 | 38.1% | n.d | PCR | Furrer et al., 2006 [109] | Argentina | Oscc | 14 | 42.8% | 16, 18 | PCR/SB | Koyama et al., 2007 [110] | Japan | Oscc | 20 | 100% | 18, 22, 16, 70 | PCR | Sugiyama et al., 2007 [111] | Japan | Oscc | 66 | 100% | 16 | PCR | Luo et al., 2007 [112] | Taiwan | Oscc | 51 | 73% | — | PCR |
Khovidhunkit et al., 2008 [113] | Thailand | Oscc | 65 | 1.54% | 16, 18 | PCR |
Szarka et al., 2009 [114] | Hungary | Oscc | 65 | 47.7% | 16, 18 | PCR |
Zhao et al., 2009 [115] | China | Oscc | 52 | 40.4% | 16, 18, 11, 6 | PCR | Attner et al., 2010 [116] | Sweden | Oscc | 87 | 68 (78)% | 16, 33 | PCR |
Elango et al., 2011 [117] | India | Oscc | 60 | 48% | 16 | PCR/IHC |
Kristoffersen et al., 2012 [118] | Norway | Oscc | 50 | 30% | 6, 11, 16 | PCR | Chen et al., 2012 [119] | Taiwan | Oscc | 64 | 39% | 16 | ISH/IHC | Lee et al., 2012 [120] | Taiwan | Oscc | 173 | 22% | 16, 18 | PCR |
|
|